(Reuters) -Drugmaker Eli Lilly is in advanced talks to acquire gene-editing startup Verve Therapeutics for up to $1.3 billion ...

HHS Secretary Robert F. Kennedy Jr. places anti-vaxxers in control of U.S. vaccine policy, slandering an actual expert along ...

A Roots Analysis study showed the market for ADC manufacturing is $1.79 billion today, but is expected to grow to $7 billion ...

The biopharma company—whose US headquarters is in Atlanta—will be building a new biologics manufacturing facility in a city ...

Biogen has emerged as a potential front-runner at the Cannes Lions International Festival of Creativity, snagging four spots ...

There’s reason to remain bullish about Merck’s growth prospects in the long run. And at a discounted price, the stock could ...

Shares of pharmaceutical company Merck (NYSE: MRK) were recently down about 40% over the past year, partly due to concerns ...

The new project voted ahead by township officials Monday night is planned for roughly a block east, in the Merck campus on ...

The Dow Jones Industrial Average (DJINDICES: ^DJI) index edged 3.9% higher in May, with 70% of its 30 constituent stocks ...

Benchling announced a new collaboration with Merck, known as MSD outside of the United States and Canada, to implement a ...

Three of the health secretary’s picks to replace fired members of an influential panel that sets U.S. vaccine policies have ...